Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
← catalyst calendarNCT07204275 · readout in 863 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →. With Zai Lab (Shanghai) Co., Ltd. (for China only).
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
176estimated
Sites
111
Countries
Australia, Brazil, China +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2028-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Membranous Nephropathy
Interventions
- Drug: Povetacicept
- Drug: Tacrolimus
Primary outcome
what the primary-completion date above is the date OFProportion of Participants with Complete Clinical Remission Definition 1 (CR1)
measured At Week 104
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed